2020.10.14

Genomtec starts public offer

Genomtec S.A. has launched an initial public offering of up to 730,000 J-series shares. The maximum price per share was agreed at PLN 11. The ...
2020.09.29

Genomtec S.A. presents its flagship diagnostic platform – Genomtec ID

Work on the mobile diagnostic platform – Genomtec ID, began in 2017 and currently we are starting its industrialization, proudly presenting ...
2020.09.25

Genomtec S.A. is being strengthened by joining key personnel – welcome to Jarek Oleszczuk, M.D., PhD, Marta Gajęcka and Jakub Swadźba, M.D., PhD.

Due to the dynamic growth in space the of company’s flagship project – Genomtec ID, the Management Board, fulfilling expectations of its ...
2020.08.31

Our plan is to debut on the NewConnect market, the Warsaw Stock Exchange, by the end of 2020 year

We would like to kindly inform you on our plans to adjust Company’s organizational structure to comply with all the conditional regulatory ...
2020.06.26

Genomtec commercializes its first genetic laboratory kit for rapid detection of SARS-CoV-2

Genomtec® SARS-CoV-2 RT-LAMP/N CE-IVD laboratory kit is our first product in the SARS-CoV-2 pipeline. After just over 10 weeks of hard work we ...
2019.12.10

MicroRNA-based tool for non-invasive early-stage cancer diagnosis — GenomtecTumor

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 885874 The ...